These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27389169)

  • 1. Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice.
    Paes W; Brown N; Brzozowski AM; Coler R; Reed S; Carter D; Bland M; Kaye PM; Lacey CJN
    Vaccine; 2016 Jul; 34(35):4123-4131. PubMed ID: 27389169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
    Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
    Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge.
    Picard MD; Cohane KP; Gierahn TM; Higgins DE; Flechtner JB
    Vaccine; 2012 Jun; 30(29):4387-93. PubMed ID: 22682294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
    Paes W; Dowle A; Coldwell J; Leech A; Ganderton T; Brzozowski A
    PLoS One; 2018; 13(6):e0198662. PubMed ID: 29912892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
    Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
    Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune memory by a multisubunit chlamydial vaccine.
    Eko FO; Ekong E; He Q; Black CM; Igietseme JU
    Vaccine; 2011 Feb; 29(7):1472-80. PubMed ID: 21184858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane protein adjuvanted with poly I:C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral immune responses.
    Khan SA; Waugh C; Rawlinson G; Brumm J; Nilsson K; Gerdts V; Potter A; Polkinghorne A; Beagley K; Timms P
    Vaccine; 2014 Oct; 32(44):5781-6. PubMed ID: 25196393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology.
    O'Meara CP; Armitage CW; Andrew DW; Kollipara A; Lycke NY; Potter AA; Gerdts V; Petrovsky N; Beagley KW
    Vaccine; 2017 Jul; 35(31):3883-3888. PubMed ID: 28602608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
    Andrew DW; Hafner LM; Beagley KW; Timms P
    J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice.
    Li Z; Wang S; Wu Y; Zhong G; Chen D
    Sci China C Life Sci; 2008 Nov; 51(11):973-80. PubMed ID: 18989639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming.
    McEntee CP; Moran HBT; Muñoz-Wolf N; Liddicoat AM; Carroll EC; Erbo-Wern J; Coulter IS; Andersen P; Follmann F; Lavelle EC
    Vaccine; 2020 Jan; 38(3):635-643. PubMed ID: 31727505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.
    Pan Q; Pais R; Ohandjo A; He C; He Q; Omosun Y; Igietseme JU; Eko FO
    Vaccine; 2015 Apr; 33(15):1865-72. PubMed ID: 25698486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
    Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.
    Lu H; Xing Z; Brunham RC
    J Immunol; 2002 Dec; 169(11):6324-31. PubMed ID: 12444139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.
    Yu H; Karunakaran KP; Jiang X; Brunham RC
    Vaccine; 2014 Aug; 32(36):4672-80. PubMed ID: 24992718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2010 Feb; 28(7):1668-72. PubMed ID: 20026449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.